INTRODUCTION
Congenital heart defects/diseases (CHD) refer to a broad range of heart development anomalies. Tetralogy of Fallot (TOF), ventricular septal defects (VSD), and atrial septal defects (ASD) are the most common CHD for newborn; other defects such as transposition of the great arteries (TGA) are less commonly seen. Congenital heart defects affect approximately 1% of live births, and are the leading cause of infant deaths. [1] [2] [3] [4] Hence, early diagnosis of fetal CHD is of great signifi cance for timely postnatal surgical intervention or termination of pregnancy. [5, 6] Accordingly, novel biomarkers for the improvement of efficiency and accuracy in the diagnosis of fetal CHD are needed in combination with conventional fetal echocardiography. [7, 8] In the new era of non-invasive prenatal tests, potential biomarkers such as microRNAs, [9, 10] proteins, [11] and the merging fetal cells [12] in maternal circulation that will cause minimum risk to fetus are easily accepted. [13] MicroRNAs are a class of non-coding RNAs of approximately 22 nucleotides in length. [14] The posttranslational regulatory roles of microRNAs have been shown in almost all physiological processes via non-precise complementary binding to the 3'un-translated region of target mRNA, which results in translation repression or mRNA degradation. [14] Taking advantage of the remarkable stability of microRNAs in serum and body fluids [15] and the dysregulated expression of microRNAs under disease conditions, [16] many studies have proposed microRNAs as diagnostic and prognostic biomarkers. [17, 18] Recently, a few prospective studies have revealed the altered expression of microRNAs in heart tissue/ plasma of patients with CHD versus CHD-free controls (Table 1) . These studies have highlighted the potential of circulating microRNAs as biomarkers for diagnosis of (fetal) CHD, and thus they are listed and discussed in this review.
Altered microRNAs in cardiac tissue of CHD

Altered microRNAs in Tetralogy of Fallot
Tetralogy of Fallot is one of the most common CHD characterized by severe heart malformations. O'Brien and colleagues [19] performed microarray analyses to screen microRNAs differentially expressed in the right ventricular myocardium of infants with non-syndromic TOF (without a 22q11.2 deletion) compared with infants with normally developing hearts. Results showed that the levels of 61 microRNAs significantly changed and miR-1275, miR-27b, miR-421, miR-1201, and miR-122 exhibited the most appreciable alterations. Their followup studies focused on miR-421. By knocking down and over-expressing miR-421 in primary cells derived from the right ventricular of TOF heart, the authors found an inverse correlation between the level of miR-421 and that of SOX4. [20] As a key regulator in Notch pathway, SOX4 affects the cardiac outfl ow track. [21] Therefore, the interplay between miR-421 and SOX4 possibly suggests the association of miR-421 with congenital heart defects.
MiR-940 is another microRNA that has been associated with TOF. Liang et al [22] identified 75 dysregulated microRNAs in TOF tissue relative to heart tissue of healthy subjects. Among the 75 microRNAs, m i R -9 4 0 w a s t h e m o s t d o w n -r e g u l a t e d o n e . [ 2 2 ] Mechanism studies showed that miR-940 negatively regulates the proliferation and migration of human cardiomyocyte progenitor cells, possibly via modulating the endogenous level of JARID2. [22] He et al [23] studied miR-138, a microRNA involved in hypoxia response of cardiomyocytes. They showed that the expression of miR-138 in myocardial samples of patients in the cyanotic group (TOF) was as almost two-fold as that of patients in the acyanotic group (VSD combined with RVOS). [23] This finding suggests that miR-138 might be used to discriminate TOF from other subtypes of CHD.
Zhang and colleagues [24] initially identified 41 candidate microRNAs with differential expression between TOF tissue and normal heart tissue. After validation in another independent population of patients with TOF, 18 out of the 41 microRNAs were found to have significant alterations at their expression levels. [24] In the study, miR-424/424 * and miR-222 were shown to affect cardiomyocyte proliferation and differentiation. [24] MicroRNAs associated with ventricular defects Yu et al [25] profi led the microRNAs in cardiac tissue of aborted fetus with single ventricle defects (VD) by using deep sequencing. As a result, 48 microRNAs
Authors
Samples for initial screening Method Altered microRNAs Bittel et al [19, 20] Right ventricular (RV) myocardium from infants with TOF (n=16) versus normally developing hearts (n=8)
MicroRNA array; qRT-PCR 61 microRNAs including miR-421, -1275, -27b, -1201, and-122 Liang et al [22] Right ventricular out-flow tract tissues of TOF (n=10) versus proximal ventricular tissue of healthy subjects (n=8)
MicroRNA array; qRT-PCR 75 microRNAs including miR-940
He et al [23] Biopsy of right ventricular out-fl ow tract of cyanotic (TOF) patients versus acyanotic (VSD+RVOS)
qRT-PCR miR-138
Zhang et al [24] Myectomy tissues from right ventricular out-flow tract (RVOT) obstruction of infants with TOF versus age-matched normal RVOT tissue MicroRNA array; qRT-PCR 41 candidate miRNAs, of which 18 were validated (miR-424/424, -222)
Yu et al [25] Cardiac tissue from the ventricles of aborted fetuses (20) (21) (22) [26] Cardiac tissue from VSD patients (n=28) versus cardiac tissue from healthy individuals (n=9)
qRT-PCR miR-1-1 and miR-181c
Wang et al [27] 28 CHD samples (4 atrium, 3 ventricle, 1 auricle, 2 ventricular septum, 10 outlet, and 8 aorta samples) versus 9 normal heart tissue samples qRT-PCR miR-10a, miR-10b
Lai et al [28] Serum samples of systemic right ventricular (n=5) versus serum samples of healthy controls (n=5) [29] Venous blood of 3 patients with VSD versus 3 VSDfree controls
MicroRNA microarray and qRT-PCR 15 microRNAs upregulated and 21 microRNAs down-regulated; 8 microRNAs (let-7e-5p, miR-222-3p, miR-433) were further validated de la Morena et al [30] Peripheral blood of patients with 22q11.2 deletion syndrome (n=31) compared to normal controls (n=22)
MicroRNA arrays 18 microRNA with differential expression; miR-185 was 0.4X fold of normal levels Zhu et al [31] Pooled maternal serum of 3 pregnant women with fetal CHD versus 3 normal pregnancies (18-22 weeks of gestation) SOLiD sequencing; qRT-PCR Four microRNAs (miR-19b, -22, -29c, and -375) upregulated Table 1 . Publications with respect to microRNAs in heart tissue/plasma of patients with CHD World J Emerg Med, Vol 7, No 2, 2016 were identified with differential expression in VD tissue compared with normal cardiac tissue. Of these microRNAs, 38 microRNAs were downregulated, and 10 microRNAs were upregulated. The increase of miR-214, miR-19b, and miR-126 and decrease of miR-200, miR-10, and miR-206 were further confirmed by qRT-PCR analysis. [25] Li et al [26] selected a set of 25 candidate microRNAs based on the initial microarray data and analyzed the relative levels of the microRNAs in heart tissue of patients with ventricular septal defects (VSD) to those in heart tissue of healthy controls by using qRT-PCR. They found that miR-1-1 and miR-181c were the most differentially expressed microRNAs for their samples. Moreover, they showed that the decrease of miR-1-1 expression was associated with the increased levels of GJA1 and SOX9, and that the increased miR-181c expression was linked with the down-regulation of BMPR2 in VSD samples. [26] MiR-10a and miR-10b in CHD Wang et al [27] first found that TBX5, which is a key transcription factor playing a role in heart development, was a target gene of both miR-10a and miR-10b. This finding encouraged them to determine the miR-10a and miR-10b expression levels in heart tissues of CHD relative to healthy controls. Results showed that the average levels of miR-10a and miR-10b in heart tissue of CHD (n=28) were as approximately 3-fold high as those in controls (n=9). [27] However, the subtypes of heart defects were not specified in this study. A stratification analysis on the expression levels of miR-10a and miR-10b in terms of the subtypes of heart defects would be of more pathobiological signifi cance.
Circulating microRNAs as potential biomarkers for diagnosis of CHD Altered circulating microRNAs in patients with CHD
The potential of circulating microRNAs as biomarkers for diagnosis and prognosis of patients with CHD has drawn attention. Lai et al [28] did the profi ling of circulating microRNAs of serum samples from 5 patients late after atrial switch operation for complete transposition of the great arteries (TGA) and 5 healthy controls, which resulted in 23 microRNAs identified with differential expression between the two groups. Subsequent validation in 26 patients and 20 controls confirmed the up-regulation of 11 of the 23 microRNAs. [28] In the study by Li et al, [29] microRNA array initially was employed to determine the differential microRNAs between 3 patients with VSD and 3 VSD-free controls, which yielded a total of 36 candidate microRNAs, of which 15 were upregulated and 21 downregulated. The results of subsequent validation experiment confi rmed the up-regulation of miR-498 and down-regulation of miRlet-7e-5p, miR-155-5p, miR-222-3p, miR379-5p, miR-433, and miR-487b, and miR-409-3p in plasma samples of patients (n=20) compared with the controls (n=15). [29] By using microRNA array, de la Morena and colleagues [30] showed that 18 microRNAs were differentially expressed in peripheral blood of patients with CHD (associated with 22q11.2 deletion syndrome) relative to normal controls. The level of miR-185 in patient blood was found to be about 0.4 fold of normal level. [30] Characteristic circulating microRNAs in maternal plasma of pregnant women with fetal CHD Zhu and colleagues [31] first reported the study using circulating microRNAs for prenatal prediction of fetal CHD. In their discovery experiment, maternal serum samples of 3 pregnant women with fetal CHD were pooled, as well as the control serum samples (n=3), to screen the differential microRNAs. Eventually, 4 microRNAs (miR-19b, miR-22, miR-29c, and miR-375) were found to be elevated in maternal plasma of pregnant women with fetal CHD. [31] This study highlights the potential of circulating microRNAs as biomarkers in non-invasive prenatal test for fetal CHD.
Limitations and future studies
Congenital heart defects include a series of heart development malformations. The etiology of CHD is complex and remains largely unknown. [1, 32] This review concentrated a series of pilot studies exploring the differentially expressed microRNAs in cardiac tissue or plasma of patients with (fetal) CHD compared with the normal healthy controls. The altered microRNAs identifi ed might become biomarkers for diagnosis of CHD in the future. [18, 33] Meantime, the regulatory network and signaling pathways implicated by the altered microRNAs provide new insights into our understanding of CHD.
However, so far, we perhaps have just seen the tip of the iceberg, because we have little knowledge about the profiles of microRNAs in other subtypes of CHD rather than TOF and ventricular septal defects. Further, the altered microRNAs are quite heterogeneous between the studies, even the studies of the same subtype of heart defects (TOF or VSD). This may faithfully reflect the complex etiology of CHD and the great heterogeneity between patients with CHD, or technically be caused by the small sample size of patient pool for initial screening in these studies. There is a possibility that the microRNAs screened were biased by patients' age, gender, and category of heart defects, complications associated with CHD, or other factors, in particular when the initial sample size was very small. Additionally, it should be noted that the cardiac tissue and maternal blood samples in most of the studies are of Chinese (Asian) genetic background. Therefore, more studies are anticipated in a diverse set of ethnic backgrounds. The observations from diversified genetic backgrounds are necessary for discovery of microRNAs that will be applied to a broad range of ethnic populations. Meantime, more efforts are called for searching reliable microRNA biomarkers for CHD. The performance of candidate microRNAs should be evaluated strictly in large populations of patients and controls. We can expect that one microRNA may not give the best performance for prediction. However, a comprehensive evaluation via a panel of microRNA biomarkers is feasible and acceptable.
It is easily understood that verification of the existence of fetus microRNA in maternal circulation will support the use of maternal circulating microRNAs as biomarkers for diagnosis of fetal CHD. Actually, it has been reported that placental microRNAs can be detected in maternal circulation. [15] Therefore, the fetal microRNAs that are indicative of CHD might be released into maternal circulation and captured for analysis. Alternatively, the microRNAs could be maternally originated, but they might serve as biomarkers for fetal CHD with high sensitivity and specifi city.
In a "new era" of microRNAs, the pathobiology of microRNAs in CHD is being extensively investigated. We believe this will greatly add new knowledge to the etiology of CHD and also promote the development of circulating microRNAs as biomarkers for diagnosis of CHD and prenatal screening. 
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